Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE) August 22, 2023 -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news